Aribio Reveals AR1001 Research Results at 2023 AAIC

Aribio announced on the 13th that it will present the multi-target mechanism of action and biomarker research results of the oral dementia treatment drug 'AR1001,' currently undergoing global Phase 3 clinical trials, at the 2023 Alzheimer's Association International Conference (AAIC) held in Amsterdam, Netherlands, starting on the 16th.

Aribio's participation image at the 2023 Alzheimer's Association International Conference (AAIC) [Photo by Aribio]

AAIC is the world's largest Alzheimer's disease-related conference held annually, where leading scholars and related pharmaceutical and biotech companies from around the world gather to discuss the diagnosis and treatment of Alzheimer's disease.

Aribio's AR1001 has had abstracts related to its mechanism of action and efficacy research accepted at this year's AAIC, and will comprehensively disclose data on its multi-target mechanism, reduction effects on p-tau (tau)-181, p-tau-217, and p-tau-231?key biomarkers recently highlighted in Alzheimer's disease?as well as anti-inflammatory related data.

Key researchers from the AAIC US branch will participate directly, and numerous on-site meetings are scheduled throughout the conference period with multinational pharmaceutical companies, partners, and advisory panels and principal investigators (PIs) from various countries participating in the AR1001 global Phase 3 clinical trial (Polaris-AD) to discuss specific outcomes.

Jaejun Jung, CEO of Aribio, stated, “We previously announced significant reduction results of p-tau-181 in Phase 2 clinical trials at the Alzheimer's & Parkinson's Conference (AD/PD) last April,” adding, “Consistent results have also been demonstrated in cell and animal experiments, allowing us to clarify the multi-target mechanism effects of AR1001 more clearly.”

The global Phase 3 clinical trial of AR1001, named Polaris-AD, began dosing the first patient in the United States in December last year and is currently progressing smoothly with over 60 clinical centers across the US. The application for Phase 3 clinical trial approval has also been submitted to the Korean Ministry of Food and Drug Safety, and the Investigational New Drug (IND) approval application process is underway with the European Medicines Agency (EMA).

This content was produced with the assistance of AI translation services.